Holen Sie sich die Stockscreener-App
22.57
2.51%
-0.585
Schlusskurs vom Vortag:
$23.16
Offen:
$23.21
24-Stunden-Volumen:
463.48K
Relative Volume:
0.35
Marktkapitalisierung:
$2.77B
Einnahmen:
$460.48M
Nettoeinkommen (Verlust:
$142.80M
KGV:
19.13
EPS:
1.18
Netto-Cashflow:
$221.79M
1W Leistung:
-0.18%
1M Leistung:
+5.56%
6M Leistung:
-12.62%
1J Leistung:
+3.86%
1-Tages-Spanne:
$22.52
$23.31
1-Wochen-Bereich:
$22.52
$23.84
52-Wochen-Spanne:
$19.05
$26.58
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
Firmenname
Catalyst Pharmaceuticals Inc
Sektor
Branche
Telefon
(305) 529-2522
Adresse
355 ALHAMBRA CIRCLE, CORAL GABLES
Vergleichen Sie CPRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CPRX
Catalyst Pharmaceuticals Inc
|
22.57 | 2.85B | 460.48M | 142.80M | 221.79M | 1.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
440.32 | 112.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
698.26 | 73.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
417.61 | 56.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
893.75 | 55.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
194.55 | 41.92B | 447.02M | -1.18B | -906.14M | -6.1812 |
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-11-18 | Eingeleitet | Stephens | Overweight |
| 2024-03-14 | Eingeleitet | Citigroup | Buy |
| 2024-03-07 | Eingeleitet | BofA Securities | Buy |
| 2023-12-21 | Eingeleitet | Oppenheimer | Outperform |
| 2022-08-24 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2018-09-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-07 | Fortgesetzt | Piper Jaffray | Overweight |
| 2016-10-05 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-04-26 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2014-09-30 | Bestätigt | ROTH Capital | Buy |
| 2014-09-16 | Bestätigt | ROTH Capital | Buy |
| 2014-09-15 | Bestätigt | H.C. Wainwright | Buy |
| 2013-10-21 | Bestätigt | Aegis Capital | Buy |
| 2013-09-24 | Eingeleitet | Maxim Group | Buy |
| 2013-09-06 | Bestätigt | Aegis Capital | Buy |
| 2013-04-18 | Eingeleitet | Aegis Capital | Buy |
| 2012-08-27 | Hochstufung | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
| 2009-10-01 | Hochstufung | Merriman | Sell → Neutral |
| 2009-05-29 | Herabstufung | Hapoalim | Neutral → Underperform |
| 2009-05-29 | Herabstufung | Merriman Curhan Ford | Buy → Sell |
| 2008-12-15 | Eingeleitet | Merriman Curhan Ford | Buy |
| 2007-11-28 | Eingeleitet | Rodman & Renshaw | Mkt Outperform |
| 2007-01-31 | Eingeleitet | Stifel Nicolaus | Buy |
| 2007-01-05 | Eingeleitet | First Albany | Buy |
Alle ansehen
Catalyst Pharmaceuticals Inc Aktie (CPRX) Neueste Nachrichten
Catalyst Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch
Transcript : Catalyst Pharmaceuticals, Inc. Presents at BofA Securities CNS Therapeutics Virtual Conference 2025, Dec-08-2025 12 - marketscreener.com
Arrowstreet Capital Limited Partnership Purchases 188,594 Shares of Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Catalyst (CPRX) Up 10% Since Last Earnings Report: Can It Continue? - sharewise.com
Kennedy Capital Management LLC Cuts Position in Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Catalyst Pharmaceutical (CPRX) Recently Broke Out Above the 20-Day Moving Average - Finviz
Should I hold or sell Catalyst Pharmaceuticals Inc. stock in 2025Earnings Recap Report & Fast Moving Stock Watchlists - Newser
Is There Still Value in Catalyst Pharmaceuticals After Its 540% Five Year Surge? - Yahoo Finance
Catalyst: Firdapse Cliff Deferred, But Capital Allocation Still An Issue (Upgrade) (CPRX) - Seeking Alpha
Catalyst Pharmaceuticals (CPRX) chair reports gifts of company stock to family trusts - Stock Titan
Will Catalyst Pharmaceuticals Inc. (CN2) stock sustain bullish trend into 2025Market Activity Recap & Weekly Momentum Picks - Newser
Franklin Resources Inc. Boosts Position in Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Can Catalyst Pharmaceuticals Inc. (CN2) stock hit consensus price targetsWeekly Trend Report & Verified Short-Term Trading Plans - Newser
CPRX SEC FilingsCatalyst Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Catalyst Pharmaceuticals (CPRX) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Transcript : Catalyst Pharmaceuticals, Inc. Presents at Citi Annual Global Healthcare Conference 2025, Dec-02-2025 01 - marketscreener.com
Why Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-Term - sharewise.com
How Catalyst Pharmaceuticals Inc. (CN2) stock behaves under inflation pressureJuly 2025 EndofMonth & High Accuracy Swing Entry Alerts - Newser
What valuation ratios show for Catalyst Pharmaceuticals Inc. (CN2) stockEarnings Recap Summary & Expert Verified Stock Movement Alerts - Newser
Catalyst Pharmaceuticals Inc. Stock Underperforms Monday When Compared To Competitors - 富途牛牛
Published on: 2025-12-02 00:32:14 - Newser
Should Value Investors Buy Catalyst Pharmaceuticals (CPRX) Stock? - sharewise.com
How Do Investors Really Feel About Catalyst Pharmaceuticals Inc? - Benzinga
Wall Street Analysts Think Catalyst (CPRX) Could Surge 47.37%: Read This Before Placing a Bet - Finviz
Skandinaviska Enskilda Banken AB publ Trims Stake in Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Legal & General Group Plc Buys 89,958 Shares of Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Elo Mutual Pension Insurance Co Takes $605,000 Position in Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Catalyst Pharmaceuticals, Inc. $CPRX Shares Bought by American Century Companies Inc. - MarketBeat
Carmen Jeffrey Del Sells 10,983 Shares of Catalyst Pharmaceuticals (NASDAQ:CPRX) Stock - MarketBeat
Catalyst Pharmaceuticals Executive Sells Shares - TradingView
Catalyst Pharmaceuticals, Inc. $CPRX Shares Bought by Advisors Asset Management Inc. - MarketBeat
A Fresh Look at Catalyst Pharmaceuticals (CPRX) Valuation Following Recent Share Price Momentum - Yahoo Finance
Catalyst Pharmaceuticals (CPRX): Assessing Valuation After Recent Share Price Gains and Pipeline Developments - Sahm
Catalyst Pharmaceuticals, Inc. $CPRX Stake Decreased by Segall Bryant & Hamill LLC - MarketBeat
Will Catalyst Pharmaceuticals Inc. stock deliver strong dividend growth2025 Market Trends & Consistent Return Strategy Ideas - moha.gov.vn
Will Catalyst Pharmaceuticals Inc. stock see insider buyingGap Down & Weekly High Return Stock Opportunities - BỘ NỘI VỤ
Summit Global Investments Reduces Stake in Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Universal Beteiligungs und Servicegesellschaft mbH Reduces Stock Holdings in Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Here's How Much a $1000 Investment in Catalyst Pharmaceutical Made 10 Years Ago Would Be Worth Today - Yahoo Finance
Magnetar Financial LLC Buys New Position in Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Catalyst Pharmaceuticals, Inc. $CPRX Shares Purchased by Geode Capital Management LLC - MarketBeat
CFO Kalb Acquires 4,409 Of Catalyst Pharmaceuticals Inc [CPRX] - TradingView
CEO Daly Acquires 12,134 Of Catalyst Pharmaceuticals Inc [CPRX] - TradingView
Officer Sundaram Acquires 4,239 Of Catalyst Pharmaceuticals Inc [CPRX] - TradingView
Officer del Carmen Acquires 3,962 Of Catalyst Pharmaceuticals Inc [CPRX] - TradingView
Catalyst Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference - Bakersfield.com
Catalyst Pharmaceuticals (Nasdaq: CPRX) at BofA CNS Therapeutics Conference Dec. 8 - Stock Titan
Catalyst Pharmaceuticals, Inc. $CPRX Stake Increased by Hillsdale Investment Management Inc. - MarketBeat
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Will Catalyst Pharmaceuticals Inc. (CN2) stock benefit from sector leadership2025 Investor Takeaways & High Accuracy Swing Entry Alerts - newser.com
LSV Asset Management Sells 126,102 Shares of Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Finanzdaten der Catalyst Pharmaceuticals Inc-Aktie (CPRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.22%
0.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):